Related Experiment Videos
Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link?
Samy I McFarlane1, Ranganath Muniyappa, John J Shin
1Department of Internal Medicine, Division of Endocrinology, SUNY-Downstate, and Kings County Hospital Center, Brooklyn, NY 11203, USA. immgss@aol.com
Insights
Osteoporosis and cardiovascular disease share underlying mechanisms, with risk factors like dyslipidemia and inflammation impacting both. Further research is needed to confirm the link between these conditions.
Area of Science:
- Endocrinology
- Cardiology
- Gerontology
Background:
- Osteoporosis and cardiovascular disease (CVD) are significant public health concerns.
- Traditionally considered separate, they share common pathophysiological pathways, particularly with aging.
- Shared risk factors include dyslipidemia, inflammation, oxidative stress, and diabetes.
Purpose of the Study:
- To explore the interconnectedness of osteoporosis and CVD.
- To review evidence linking shared risk factors and pathophysiological mechanisms.
- To discuss potential therapeutic implications for treating both conditions concurrently.
Main Methods:
- Literature review and synthesis of existing research.
- Analysis of epidemiological data and clinical trial findings.
- Examination of molecular and cellular mechanisms common to both diseases.
Main Results:
- Shared risk factors like dyslipidemia, inflammation, and hyperhomocysteinemia are associated with both low bone mineral density (LBMD) and CVD.
- Lipid metabolism, inflammation, and nitric oxide (NO) pathways play roles in both bone remodeling and atherosclerosis.
- Pharmacological agents like statins and bisphosphonates show potential in affecting both conditions.
Conclusions:
- A growing body of evidence suggests shared pathophysiological mechanisms between osteoporosis and CVD.
- While promising, the link is not yet conclusive, necessitating further investigation.
- Future research should focus on elucidating these connections to develop integrated treatment strategies.
Abstract:
Both osteoporosis and cardiovascular disease (CVD) are major public health problems leading to increased morbidity and mortality. Although traditionally viewed as separate disease entities that increase in prevalence with aging, accumulating evidence indicates that there are similar pathophysiological mechanisms underlying both diseases. In addition to menopause and advanced age, other risk factors for CVD such as dyslipidemia, oxidative stress, inflammation, hyperhomocystinemia, hypertension, and diabetes have also been associated with increased risk of low bone mineral density (LBMD). Elevated LDL and low HDL cholesterol are associated with LBMD, altered lipid metabolism is associated with both bone remodeling and the atherosclerotic process, which might explain, in part, the co-existence of osteoporosis and atherosclerosis in patients with dyslipidemia. Similarly, inflammation plays a pivotal role in both atherosclerosis and osteoporosis. Elevated plasma homocysteine levels are associated with both CVD and osteoporosis. Nitric oxide (NO), in addition to its known atheroprotective effects, appears to also play a role in osteoblast function and bone turnover. Supporting this notion, in a small randomized controlled trial, nitroglycerine (an NO donor) was found to be as effective as estrogen in preventing bone loss in women with surgical menopause. Statins, agents that reduce atherogenesis, also stimulate bone formation. Furthermore, bis- phosphonates, used in the treatment of osteoporosis, have been shown to inhibit atherogenesis. Intravenous bisphosphonate therapy significantly decreases serum LDL and increases HDL in postmenopausal women The exciting possibilities of newer pharmacological agents that effectively treat both osteoporosis and CVD hold considerable promise. However, it is important to emphasize that the current evidence linking both of these diseases is far from conclusive. Therefore, additional research is necessary to further characterize the relationship between these two common illnesses.
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
What is the Skeletal System?
Bone Remodeling
Osteoclasts in Bone Remodeling